» Articles » PMID: 16219492

Biology of AAV Serotype Vectors in Liver-directed Gene Transfer to Nonhuman Primates

Overview
Journal Mol Ther
Publisher Cell Press
Date 2005 Oct 13
PMID 16219492
Citations 88
Authors
Affiliations
Soon will be listed here.
Abstract

Vectors based on adeno-associated viruses (AAVs) show promise for the treatment of genetic diseases. This study evaluates the biology of AAV-mediated gene transfer to liver in nonhuman primates (NHPs) using vectors based on AAV serotypes 2, 7, and 8. Transgenes encoding self-proteins were selected to minimize the confounding development of transgene-specific immune responses. These included the beta subunit of choriogonadotropic hormone (bCG) and erythropoietin (Epo), both derived from cDNAs from rhesus macaques. Experiments were performed with bCG in rhesus macaques and Epo in cynomolgus macaques. We demonstrated the previously untested hypothesis that preexisting immunity to a natural infection does substantially diminish the efficacy of gene transfer with a vector derived from an endogenous virus. Route of vector administration clearly has an impact on the development of immune responses to self-antigens. In general, efficiency of gene transfer to liver with AAV7 and 8 vectors was higher than what was achieved with AAV2, although a variety of host factors may influence this important parameter, such as preexisting immunity, gender, and transgene immunity.

Citing Articles

A Penetrable AAV2 Capsid Variant for Efficient Intravitreal Gene Delivery to the Retina.

He X, Fu Y, Xu Y, Ma L, Chai P, Shi H Invest Ophthalmol Vis Sci. 2025; 66(1):6.

PMID: 39745676 PMC: 11702840. DOI: 10.1167/iovs.66.1.6.


Sleeping Beauty mRNA-LNP enables stable rAAV transgene expression in mouse and NHP hepatocytes and improves vector potency.

Zakas P, Cunningham S, Doherty A, van Dijk E, Ibraheim R, Yu S Mol Ther. 2024; 32(10):3356-3371.

PMID: 38981468 PMC: 11489535. DOI: 10.1016/j.ymthe.2024.06.021.


Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A.

Long B, Robinson T, Day J, Yu H, Lau K, Imtiaz U Mol Ther. 2024; 32(7):2052-2063.

PMID: 38796703 PMC: 11286804. DOI: 10.1016/j.ymthe.2024.05.033.


AAV5 Delivery of CRISPR/Cas9 Mediates Genome Editing in the Lungs of Young Rhesus Monkeys.

Liang S, Navia A, Ramseier M, Zhou X, Martinez M, Lee C Hum Gene Ther. 2024; 35(19-20):814-824.

PMID: 38767512 PMC: 11511778. DOI: 10.1089/hum.2024.035.


New AAV9 engineered variants with enhanced neurotropism and reduced liver off-targeting in mice and marmosets.

Giannelli S, Luoni M, Iannielli A, Middeldorp J, Philippens I, Bido S iScience. 2024; 27(5):109777.

PMID: 38711458 PMC: 11070337. DOI: 10.1016/j.isci.2024.109777.